Jul. 16 at 12:19 AM
FDA Double Countdown:
$CAPR’s Breakout Level Is
$20.93
$CAPR closed at
$20.35, down 1.6%, after a
$19.62–
$20.93 range on 1.37M shares. Volume was near average, suggesting positioning before the July 29 FDA advisory committee, not panic selling.
Deramiocel remains the thesis. HOPE-3 met its PUL 2.0 primary endpoint and all controlled secondary endpoints. Cardiac MRI showed three fewer fibrotic segments vs. placebo, p=0.022; the baseline-cardiomyopathy subgroup gained 3.3 points in LVEF, p=0.017. AdCom is July 29; PDUFA is August 22.
Q1 revenue was
$0, net loss
$33.9M and cash about
$279M, enough into Q4 2027. H.C. Wainwright targets
$60 and B. Riley
$63, but short interest near 28% keeps volatility high.
Signal: hold
$19.62 for a bounce; reclaim
$20.93 on volume for confirmation. Below
$19.62, wait. Sector read:
$SRPT fell 2.0%;
$PTCT gained 1.0%.
Charts tell the story before headlines do. Check my profile for more.
